Summary Pacific Edge Limited (PEB) is a medical diagnostics company that discovers and commercializes diagnostic and prognostic technology for the early detection and monitoring of cancer. The company has completed trials in colorectal cancer prognosis and bladder cancer detection. It identifies gene and protein signatures for the development of cancer management tools. PEB's cxbladder is a non-invasive laboratory test for the detection of bladder cancer. The company is developing prognostic gene signature for patients, who are diagnosed with stage II or stage III colorectal cancer. It is also building a range of cxbladder tests to meet different clinical needs. The company provides diagnostic services through its facilities in New Zealand, Spain, Australia and the US. P This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Scope: - The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments - The report analyzes all pipeline products in development for the company Pacific Edge Limited - The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) - The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date - The report provides detailed description of products in development, technical specification and functions - The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date. Reasons to Buy: - Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape - Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio - To formulate effective Research & Development strategies - Develop market-entry and market expansion strategies - Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc - Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Pacific Edge Limited Company Snapshot 6 Pacific Edge Limited Company Overview 6 Pacific Edge Limited Pipeline Products and Clinical Trials Overview 7 Pacific Edge Limited - Pipeline Analysis Overview 9 Key Facts 9 Pacific Edge Limited - Major Products and Services 10 Pacific Edge Limited Pipeline Products by Development Stage 11 Pacific Edge Limited Clinical Trials by Trial Status 13 Pacific Edge Limited Pipeline Products Overview 14 Cxbladder 14 Cxbladder Product Overview 14 Cxbladder - Health 15 Cxbladder - Health Product Overview 15 Cxbladder - Prognosis Assay 16 Cxbladder - Prognosis Assay Product Overview 16 Cxbladder Monitor 17 Cxbladder Monitor Product Overview 17 Cxbladder Monitor Clinical Trial 18 Cxbladder Predict 19 Cxbladder Predict Product Overview 19 CxColorectal 20 CxColorectal Product Overview 20 Cxcolorectal - prognosis Gen II 21 Cxcolorectal - prognosis Gen II Product Overview 21 Diagnostic Assay - Gastric Cancer 22 Diagnostic Assay - Gastric Cancer Product Overview 22 Endometrial Cancer Detection Assay 23 Endometrial Cancer Detection Assay Product Overview 23 Gastric Cancer Triage Immunoassay 24 Gastric Cancer Triage Immunoassay Product Overview 24 Prognostic Assay - Melanoma 25 Prognostic Assay - Melanoma Product Overview 25 Pacific Edge Limited - Key Competitors 26 Pacific Edge Limited - Key Employees 27 Pacific Edge Limited - Locations And Subsidiaries 28 Head Office 28 Other Locations & Subsidiaries 28 Recent Developments 29 Pacific Edge Limited, Recent Developments 29 May 16, 2016: Pacific Edge Presents Positive Cxbladder Monitor Results 29 May 25, 2015: Research Shows Pacific Edge's Cxbladder Detect Outperforms Other Non-Invasive Bladder Cancer Diagnostics 29 May 19, 2015: Pacific Edge's Cxbladder Triage Accurately Stratifies Patients with Bladder Cancer Symptoms but Low Probability of Bladder Cancer 30 Apr 21, 2015: Pacific Edge seeks additional laboratory accreditation as it pursues international opportunities 30 Mar 18, 2015: Pacific Edge Adds To Its Growing List Of Issued Patents 31 Mar 18, 2015: Cxbladder Triage To Be Showcased In Prestigious Medical Journal 31 Nov 28, 2014: Pacific Edge Reports Commercial Progress and Revenue Growth 32 Nov 26, 2014: Europe Grants Pacific Edge Patent For Colorectal Cancer Prognostic Technology 33 Nov 13, 2014: Pacific Edge announces appointment of Chief Financial Officer 34 Sep 04, 2014: U.S. Grants Pacific Edge Patent for Melanoma Detection 34 Appendix 36 Methodology 36 About GlobalData 36 Contact Us 36 Disclaimer 36
List of Tables
Pacific Edge Limited Pipeline Products and Clinical Trials Overview 7 Pacific Edge Limited Pipeline Products by Equipment Type 7 Pacific Edge Limited Pipeline Products by Indication 8 Pacific Edge Limited Clinical Trials by Trial Status 8 Pacific Edge Limited, Key Facts 9 Pacific Edge Limited, Major Products and Services 10 Pacific Edge Limited Number of Pipeline Products by Development Stage 11 Pacific Edge Limited Pipeline Products Summary by Development Stage 12 Pacific Edge Limited Clinical Trials by Trial Status 13 Pacific Edge Limited Clinical Trials Summary 13 Cxbladder - Product Status 14 Cxbladder - Product Description 14 Cxbladder - Health - Product Status 15 Cxbladder - Health - Product Description 15 Cxbladder - Prognosis Assay - Product Status 16 Cxbladder - Prognosis Assay - Product Description 16 Cxbladder Monitor - Product Status 17 Cxbladder Monitor - Product Description 17 Cxbladder Monitor - A Clinical, Non-intervention Study of the Cxbladder Urine Test for the Detection of Recurrent Urothelial Carcinoma (UC) 18 Cxbladder Predict - Product Status 19 Cxbladder Predict - Product Description 19 CxColorectal - Product Status 20 CxColorectal - Product Description 20 Cxcolorectal - prognosis Gen II - Product Status 21 Cxcolorectal - prognosis Gen II - Product Description 21 Diagnostic Assay - Gastric Cancer - Product Status 22 Diagnostic Assay - Gastric Cancer - Product Description 22 Endometrial Cancer Detection Assay - Product Status 23 Endometrial Cancer Detection Assay - Product Description 23 Gastric Cancer Triage Immunoassay - Product Status 24 Gastric Cancer Triage Immunoassay - Product Description 24 Prognostic Assay - Melanoma - Product Status 25 Prognostic Assay - Melanoma - Product Description 25 Pacific Edge Limited, Key Employees 27 Pacific Edge Limited, Subsidiaries 28
List of Figures
Pacific Edge Limited Pipeline Products by Equipment Type 8 Pacific Edge Limited Pipeline Products by Development Stage 11 Pacific Edge Limited Clinical Trials by Trial Status 13
Global heat transfer fluids market size is likely to be valued at USD 3.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing demand for for heat recovery management in industries such as metal processing, pharmaceuticaRead More...
Global fumaric acid market size is anticipated to be valued at USD 764.8 million by 2020, as per a new research report by Radiant Insights, Inc. Growing processed food demand coupled with RTD (ready-to-drink) beverages consumption is expected to drivRead More...
Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the demRead More...
Global Biocides market size is likely to be valued at USD 11.9 billion by 2022; as per a new research report by Radiant Insights, Inc. Growth in water treatment process units particularly in China, Japan and India is likely to drive demand. IncreasinRead More...
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.